ECSP045197A - Preparación liofilizada que contiene un anticuerpo contra el receptor EGF - Google Patents

Preparación liofilizada que contiene un anticuerpo contra el receptor EGF

Info

Publication number
ECSP045197A
ECSP045197A EC2004005197A ECSP045197A ECSP045197A EC SP045197 A ECSP045197 A EC SP045197A EC 2004005197 A EC2004005197 A EC 2004005197A EC SP045197 A ECSP045197 A EC SP045197A EC SP045197 A ECSP045197 A EC SP045197A
Authority
EC
Ecuador
Prior art keywords
antibody against
preparation containing
egf receptor
lyophilized preparation
receptor
Prior art date
Application number
EC2004005197A
Other languages
English (en)
Inventor
Hanns-Christian Mahler
Hans-Peter Zobel
Robert Mueller
Christiane Bachmann
Udo Haas
Ludwig Krueger
Ulrike Martini-Marr
Original Assignee
Merck Patent Gmbh
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Merck Patent Gmbh filed Critical Merck Patent Gmbh
Publication of ECSP045197A publication Critical patent/ECSP045197A/es

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/395—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/28—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
    • C07K16/2863—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against receptors for growth factors, growth regulators
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/02—Inorganic compounds
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/06—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
    • A61K47/08—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite containing oxygen, e.g. ethers, acetals, ketones, quinones, aldehydes, peroxides
    • A61K47/10—Alcohols; Phenols; Salts thereof, e.g. glycerol; Polyethylene glycols [PEG]; Poloxamers; PEG/POE alkyl ethers
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/06—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
    • A61K47/08—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite containing oxygen, e.g. ethers, acetals, ketones, quinones, aldehydes, peroxides
    • A61K47/12—Carboxylic acids; Salts or anhydrides thereof
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/06—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
    • A61K47/16—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite containing nitrogen, e.g. nitro-, nitroso-, azo-compounds, nitriles, cyanates
    • A61K47/18—Amines; Amides; Ureas; Quaternary ammonium compounds; Amino acids; Oligopeptides having up to five amino acids
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/06—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
    • A61K47/16—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite containing nitrogen, e.g. nitro-, nitroso-, azo-compounds, nitriles, cyanates
    • A61K47/18—Amines; Amides; Ureas; Quaternary ammonium compounds; Amino acids; Oligopeptides having up to five amino acids
    • A61K47/183—Amino acids, e.g. glycine, EDTA or aspartame
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/06—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
    • A61K47/26—Carbohydrates, e.g. sugar alcohols, amino sugars, nucleic acids, mono-, di- or oligo-saccharides; Derivatives thereof, e.g. polysorbates, sorbitan fatty acid esters or glycyrrhizin
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/0012—Galenical forms characterised by the site of application
    • A61K9/0019—Injectable compositions; Intramuscular, intravenous, arterial, subcutaneous administration; Compositions to be administered through the skin in an invasive manner
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/14—Particulate form, e.g. powders, Processes for size reducing of pure drugs or the resulting products, Pure drug nanoparticles
    • A61K9/19—Particulate form, e.g. powders, Processes for size reducing of pure drugs or the resulting products, Pure drug nanoparticles lyophilised, i.e. freeze-dried, solutions or dispersions
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/505—Medicinal preparations containing antigens or antibodies comprising antibodies

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • Epidemiology (AREA)
  • Engineering & Computer Science (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Oil, Petroleum & Natural Gas (AREA)
  • Immunology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Organic Chemistry (AREA)
  • Biochemistry (AREA)
  • Molecular Biology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Dermatology (AREA)
  • Inorganic Chemistry (AREA)
  • Biophysics (AREA)
  • Genetics & Genomics (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Microbiology (AREA)
  • Mycology (AREA)
  • Medicinal Preparation (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
  • Peptides Or Proteins (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)

Abstract

La invención se refiere a una preparación farmacéutica liofilizada que contiene un anticuerpo contra el receptor del factor de crecimiento endotelial (receptor EGF). La preparación presenta una mayor estabilidad al almacenamiento incluso a altas temperaturas y puede utilizarse en forma parenteral para el tratamiento de tumores luego de su reconstitución.
EC2004005197A 2001-12-21 2004-07-20 Preparación liofilizada que contiene un anticuerpo contra el receptor EGF ECSP045197A (es)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
DE10163459A DE10163459A1 (de) 2001-12-21 2001-12-21 Lyophilisierte Zubereitung enthaltend Antikörper gegen EGF-Rezeptor

Publications (1)

Publication Number Publication Date
ECSP045197A true ECSP045197A (es) 2004-08-27

Family

ID=7710502

Family Applications (1)

Application Number Title Priority Date Filing Date
EC2004005197A ECSP045197A (es) 2001-12-21 2004-07-20 Preparación liofilizada que contiene un anticuerpo contra el receptor EGF

Country Status (26)

Country Link
US (2) US20050220786A1 (es)
EP (1) EP1455824B1 (es)
JP (1) JP2005513110A (es)
KR (1) KR100942399B1 (es)
CN (1) CN100515495C (es)
AR (1) AR037971A1 (es)
AT (1) ATE403439T1 (es)
AU (1) AU2002358533B2 (es)
BR (1) BR0215266A (es)
CA (1) CA2470316A1 (es)
CO (1) CO5590939A2 (es)
DE (2) DE10163459A1 (es)
EC (1) ECSP045197A (es)
ES (1) ES2309220T3 (es)
HU (1) HUP0402192A2 (es)
IL (1) IL162588A0 (es)
MX (1) MXPA04006059A (es)
MY (1) MY139055A (es)
NZ (1) NZ534211A (es)
PE (1) PE20030777A1 (es)
PL (1) PL205982B1 (es)
RU (1) RU2339402C2 (es)
TW (1) TWI318884B (es)
UA (1) UA83461C2 (es)
WO (1) WO2003053465A2 (es)
ZA (1) ZA200405785B (es)

Families Citing this family (35)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US7060808B1 (en) * 1995-06-07 2006-06-13 Imclone Systems Incorporated Humanized anti-EGF receptor monoclonal antibody
US20030224001A1 (en) * 1998-03-19 2003-12-04 Goldstein Neil I. Antibody and antibody fragments for inhibiting the growth of tumors
ZA200007412B (en) * 1998-05-15 2002-03-12 Imclone Systems Inc Treatment of human tumors with radiation and inhibitors of growth factor receptor tyrosine kinases.
HK1047236A1 (zh) * 1999-05-14 2003-02-14 Imclone Llc 用表皮生长因子受体拮抗剂治疗难治的人肿瘤
JP2004527456A (ja) * 2000-08-09 2004-09-09 イムクローン システムズ インコーポレイティド Ｅｇｆ受容体拮抗剤による過増殖性の疾患の治療
US20080008704A1 (en) * 2001-03-16 2008-01-10 Mark Rubin Methods of treating colorectal cancer with anti-epidermal growth factor antibodies
CA2447851C (en) * 2001-06-28 2012-08-28 Domantis Limited Dual-specific ligand and its use
US9321832B2 (en) * 2002-06-28 2016-04-26 Domantis Limited Ligand
US7696320B2 (en) 2004-08-24 2010-04-13 Domantis Limited Ligands that have binding specificity for VEGF and/or EGFR and methods of use therefor
EP1517921B1 (en) * 2002-06-28 2006-06-07 Domantis Limited Dual specific ligands with increased serum half-life
EP1578801A2 (en) * 2002-12-27 2005-09-28 Domantis Limited Dual specific single domain antibodies specific for a ligand and for the receptor of the ligand
EP1622941A2 (en) * 2003-03-20 2006-02-08 ImClone Systems Incorporated Method of producing an antibody to epidermal growth factor receptor
DE10355251A1 (de) * 2003-11-26 2005-06-23 Merck Patent Gmbh Pharmazeutische Zubereitung enthaltend einen Antikörper gegen den EGF-Rezeptor
DE10355904A1 (de) 2003-11-29 2005-06-30 Merck Patent Gmbh Feste Formen von anti-EGFR-Antikörpern
CN1953768B (zh) * 2004-02-12 2010-10-13 默克专利有限公司 抗-egfr抗体的高浓缩液体制剂
PT1735348E (pt) * 2004-03-19 2012-07-24 Imclone Llc Anticorpo anti-receptor do factor de crescimento humano
JP2008519757A (ja) * 2004-11-12 2008-06-12 メルク パテント ゲゼルシャフト ミット ベシュレンクテル ハフトング 抗ｅｇｆｒ抗体の固形物
EP2377554A1 (en) * 2005-07-22 2011-10-19 Amgen, Inc Concentrated protein lyophilates, methods and uses
CN101454344A (zh) * 2005-12-01 2009-06-10 杜门蒂斯有限公司 与白细胞介素-1受体1型结合的非竞争性域抗体形式
US9309316B2 (en) 2005-12-20 2016-04-12 Bristol-Myers Squibb Company Stable subcutaneous protein formulations and uses thereof
TW200738261A (en) * 2005-12-20 2007-10-16 Bristol Myers Squibb Co Stable protein formulations
EP2029163A4 (en) * 2006-06-14 2010-08-11 Imclone Llc LYOPHILIZED FORMULATIONS OF ANTI-EGFR ANTIBODIES
JPWO2008029908A1 (ja) * 2006-09-07 2010-01-21 協和発酵キリン株式会社 抗体を含有する安定な凍結乾燥医薬製剤
CA2665567C (en) * 2006-10-06 2012-07-03 Amgen Inc. Stable formulations
CA2666492C (en) * 2006-10-20 2012-07-17 Douglas Rehder Stable polypeptide formulations
WO2008149147A2 (en) 2007-06-06 2008-12-11 Domantis Limited Polypeptides, antibody variable domains and antagonists
CN101716343A (zh) * 2008-10-09 2010-06-02 哈药集团生物工程有限公司 一种单克隆抗体的冻干制剂
MX352025B (es) 2011-02-11 2017-11-07 Merck Patent Gmbh Anticuerpo anti-integrina alfa v para el tratamiento de cancer de prostata.
CA2830806C (en) * 2011-03-31 2020-05-12 Merck Sharp & Dohme Corp. Stable formulations of antibodies to human programmed death receptor pd-1 and related treatments
UA116189C2 (uk) 2011-05-02 2018-02-26 Мілленніум Фармасьютікалз, Інк. КОМПОЗИЦІЯ АНТИ-α4β7 АНТИТІЛА
PE20191242A1 (es) 2011-10-25 2019-09-16 Prothena Biosciences Ltd Formulaciones de anticuerpo y metodos
ES2962373T3 (es) * 2016-04-13 2024-03-18 Medimmune Llc Uso de aminoácidos como compuestos estabilizadores en composiciones farmacéuticas que contienen altas concentraciones de agentes terapéuticos basados en proteínas
JP7042220B2 (ja) 2016-12-28 2022-03-25 Ｊｃｒファーマ株式会社 凍結乾燥製剤
SG11202011538RA (en) * 2018-06-01 2020-12-30 Rakuten Medical Inc Phthalocyanine dye conjugate compositions
WO2020079209A1 (en) 2018-10-19 2020-04-23 Merck Patent Gmbh Abituzumab for the treatment of colorectal cancer

Family Cites Families (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
DE4242863A1 (de) * 1992-12-18 1994-06-23 Boehringer Mannheim Gmbh Stabile lyophilisierte pharmazeutische Zubereitungen von G-CSF
EP0852951A1 (de) * 1996-11-19 1998-07-15 Roche Diagnostics GmbH Stabile lyophilisierte pharmazeutische Zubereitungen von mono- oder polyklonalen Antikörpern
KR100215027B1 (ko) * 1997-01-27 1999-08-16 성재갑 스테로이드계 약물의 경피흡수투여용 조성물 및 이를 포함하는 경피흡수투여용 제형
US6627196B1 (en) * 1999-08-27 2003-09-30 Genentech, Inc. Dosages for treatment with anti-ErbB2 antibodies

Also Published As

Publication number Publication date
HUP0402192A2 (hu) 2005-01-28
WO2003053465A2 (de) 2003-07-03
JP2005513110A (ja) 2005-05-12
MY139055A (en) 2009-08-28
UA83461C2 (uk) 2008-07-25
AR037971A1 (es) 2004-12-22
DE10163459A1 (de) 2003-07-03
RU2004122632A (ru) 2005-05-20
EP1455824A2 (de) 2004-09-15
PL369848A1 (en) 2005-05-02
TWI318884B (en) 2010-01-01
BR0215266A (pt) 2004-12-07
KR20040074099A (ko) 2004-08-21
CO5590939A2 (es) 2005-12-30
MXPA04006059A (es) 2004-09-27
TW200306205A (en) 2003-11-16
PL205982B1 (pl) 2010-06-30
RU2339402C2 (ru) 2008-11-27
KR100942399B1 (ko) 2010-02-17
IL162588A0 (en) 2005-11-20
NZ534211A (en) 2006-01-27
AU2002358533B2 (en) 2009-01-15
US20080166346A1 (en) 2008-07-10
PE20030777A1 (es) 2003-09-11
HK1071306A1 (zh) 2005-07-15
CN100515495C (zh) 2009-07-22
CA2470316A1 (en) 2003-07-03
WO2003053465A3 (de) 2003-12-04
ES2309220T3 (es) 2008-12-16
ATE403439T1 (de) 2008-08-15
EP1455824B1 (de) 2008-08-06
AU2002358533A1 (en) 2003-07-09
CN1606455A (zh) 2005-04-13
ZA200405785B (en) 2005-06-29
US20050220786A1 (en) 2005-10-06
DE50212615D1 (de) 2008-09-18

Similar Documents

Publication Publication Date Title
ECSP045197A (es) Preparación liofilizada que contiene un anticuerpo contra el receptor EGF
TW200531702A (en) Pharmaceutical preparation comprising an antibody against the egf receptor
ES2621211T3 (es) Composiciones inmunogénicas que comprenden polipéptidos de mycobacterium tuberculosis y fusiones de los mismos
CY1121230T1 (el) Φαρμακευτικες συνθεσεις που περιεχουν οξειδιο-υδροξειδιο του σιδηρου
CY1121125T1 (el) Συνθεσεις για τη θεραπευτικη αντιμετωπιση του πονου και/ή της φλεγμονης
EA200200954A1 (ru) Композиция
PA8623601A1 (es) Protector para punta de aguja
ES2721148T3 (es) Composiciones farmacéuticas de paclitaxel, análogos de paclitaxel o conjugados de paclitaxel y métodos relacionados de preparación y uso
AR096115A1 (es) Modificaciones cristalinas del elobixibat
CY1107457T1 (el) Εμβoλιο κατa του hpv
PE20120359A1 (es) Formulacion con anticuerpo
PL377720A1 (pl) Soczewka wewnątrzgałkowa i iniektor do tej soczewki
AR059203A1 (es) Composiciones para uso vaginal
CL2007001752A1 (es) Compuesto 4-[5(2-amino-etansulfonil)-isoquinolin-7-il]-fenolo una sal farmaceuticamente aceptable o un hidrato o la sal del mismo;composicion farmaceutica que comprende a dicho compuesto,composicion farmaceutica liofilizada;y uso del compuesto como antineiplasico y/o antiviral.
BRPI0503829A (pt) artigos absorventes descartáveis enrolados
AR038355A1 (es) Preparacion liofilizada que comprende inmunocitoquinas
ATE450884T1 (de) Hochdruckentladungslampe
AR050938A1 (es) Articulos absorbentes desechables
MX2008011844A (es) Formulaciones de sitaxsentano de sodio.
WO2009148678A3 (en) Optical cavity furnace for semiconductor wafer processing
ATE515207T1 (de) Cremetiegel
UY26648A1 (es) Inhibidores de vasopeptidasa para tratar hipertensión sistólica aislada
EA200702079A1 (ru) Вакцина
AR037304A1 (es) Composiciones liofilizadas de anticuerpos monoclonales
CO5660272A2 (es) Vacunas bovinas con adyuvantes